News

The safety profile observed in this trial is consistent with other trials of Arzerra and no new safety signals were observed. "Patients eventually stop responding to current CLL

Caliber’s production will be used for IND-enabling toxicology studies and initial human clinical trials of IBIO-CFB03. iBio is the exclusive worldwide licensee of the patents developed by Dr.

The subject patent claims cover CBDV, a non-psychoactive cannabinoid extracted from the cannabis plant, for use in the treatment of patients with epilepsy and specifically for the control

Nicorette mini Lozenge, a mini-sized stop-smoking lozenges, can double smokers’ chances of quitting and it comes in a discreet pocket-size vial so smokers can have it on hand

Under the deal, 4DMT will deploy its AAV vector discovery platform, Directed Vector Evolution, to discover and optimize new gene delivery vectors for use in gene therapy products.

Both invasive aspergillosis and mucormycosis are life-threatening fungal infections predominantly occurring in immunocompromised patients. In March 2015, the US Food and Drug Administration (FDA) approved a new drug

Motolimod is a new Toll-like Receptor 8 (TLR8) agonist that directly activates multiple components of the innate immune system, which includes human myeloid dendritic cells (mDCs), monocytes and

The company is seeking US marketing approval of MM-398 to treat patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. Earlier, Merrimack

Additionally, the CHMP has recommended approval of Lixiana to treat deep vein thrombosis (DVT) and pulmonary embolism (PE) as well as to prevent recurrent DVT and PE in